Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

140.07
BATS BZX Real-Time Price
As of 3:26pm ET
 -1.12 / -0.79%
Today’s Change
133.64
Today|||52-Week Range
176.85
-13.71%
Year-to-Date
I'm Buying Biotech on This Trump Scare
11:05am / TheStreet.com - Paid Partner Content
Momenta/Shire's Humira Biosimilar Meets Study Objective
Nov 30 / Zacks.com - Paid Partner Content
Stock Market News for December 08, 2016
10:51am / Zacks.com - Paid Partner Content
Better Buy: Biogen Inc. vs. Amgen
Nov 30 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
Dec 07 / Zacks.com - Paid Partner Content
Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
Nov 30 / Zacks.com - Paid Partner Content
Better Buy: Amgen Inc. vs. Pfizer
Dec 07 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for...
Nov 30 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH
Dec 06 / Zacks.com - Paid Partner Content
3 Top Dividend Stocks to Buy in 2017
Nov 29 / MotleyFool.com - Paid Partner Content
Amgen/Allergan File for EU Approval of Avastin Biosimilar
Dec 05 / Zacks.com - Paid Partner Content
'Brain training' healthcare digital games target dementia
Nov 29 / FT.com - Paid Partner Content
Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
Dec 04 / TheStreet.com - Paid Partner Content
Merck: Keytruda's Priority Review for New Cancer Indication
Nov 29 / Zacks.com - Paid Partner Content
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
Dec 02 / Zacks.com - Paid Partner Content
Trump's Presidency: The Worst Thing Investors Can Do Now
Nov 26 / MotleyFool.com - Paid Partner Content
Here's Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today
Nov 30 / MotleyFool.com - Paid Partner Content
Clinton defeat provides antidote to US drugmakers
Nov 10 / FT.com - Paid Partner Content